Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 19/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 18/20 | 1.00 |
| ▸ | PDE4A | P27815 | 15/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 15/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 0.70 |
| ▸ | TNF | P01375 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29603817 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1194547 | 1.00 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL9977589 | 0.91 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1194004 | 0.91 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537805 | 0.90 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537071 | 0.90 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL29372989 | 0.90 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1566155 | 0.89 | PDE4B (0.81) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1193944 | 0.89 | PDE4B (0.81) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL28453492 | 0.89 | PDE4B (0.80) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11266628-B2 | Pharmaceutical compositions of apremilast | UNICHEM LABORATORIES LTD (IN) | 2022-03-08 | — | — | US | disclosed |
| US-20200261416-A1 | PHARMACEUTICAL COMPOSITIONS OF APREMILAST | UNICHEM LABORATORIES LTD (IN) | 2020-08-20 | — | — | US | disclosed |
| WO-2012083153-A1 | OLIGOMER-CONTAINING APREMILAST MOIETY COMPOUNDS | NEKTAR THERAPEUTICS (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11266628-B2 | Pharmaceutical compositions of apremilast | TNF, APRT, TPMT | PDE4B 146/4885PDE4C 433/4885PDE4A 196/4885 |
| US-20200261416-A1 | PHARMACEUTICAL COMPOSITIONS OF APREMILAST | TNF, APRT, TPMT | PDE4B 146/4885PDE4C 433/4885PDE4A 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.